| Systematic (IUPAC) name | |
|---|---|
| (5α,6E)- 3,14-dihydroxy- 17-methyl- 4,5-epoxy- morphinan- 6-one hydrazone | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 73697-35-5 |
| ATC code | None |
| PubChem | CID 9577748 |
| Synonyms | Oxymorphone hydrazone |
| Chemical data | |
| Formula | C17H21N3O3 |
| Mol. mass | 315.367 g/mol |
| SMILES | eMolecules & PubChem |
| |
|
Oxymorphazone is an opioid analgesic drug related to oxymorphone. Oxymorphazone is a potent and long acting μ-opioid agonist which binds irreversibly to the receptor, forming a covalent bond which prevents it from detaching once bound.[1][2] This gives it an unusual pharmacological profile, and while oxymorphazone is only around half the potency of oxymorphone, with higher doses the analgesic effect becomes extremely long lasting, with a duration of up to 48 hours.[3] However, tolerance to analgesia develops rapidly with repeated doses,[4][5][6] as chronically activated opioid receptors are rapidly internalised by β-arrestins, similar to the results of non-covalent binding by agonists with extremely high binding affinity such as lofentanil.[7][8]
| This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)